Entera Bio appoints Geno J. Germano as Chairman with Pfizer experience, advancing programs towards 2026 milestones.
Entera welcomes a new chairman to their board, bringing extensive global leadership experience from prominent biopharma companies like Pfizer and Wyeth. The new addition signals Entera's progression as they work towards achieving significant milestones in 2026 with multiple oral peptide programs. This development marks a pivotal moment for Entera as they strive to drive innovation and growth in the biopharmaceutical industry, leveraging the expertise and insights of their new chairman to propel their initiatives forward.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments